Login / Signup

Pharmacoproteomic characterisation of human colon and rectal cancer.

Martin FrejnoRiccardo Zenezini ChiozziMathias WilhelmHeiner KochRunsheng ZhengSusan KlaegerBenjamin RuprechtChen MengKarl KramerAnna JarzabStephanie HeinzlmeirElaine JohnstoneEnric DomingoDavid KerrMoritz JesinghausJulia Slotta-HuspeninaWilko WeichertStefan KnappStephan M FellerBernhard Kuster
Published in: Molecular systems biology (2017)
Most molecular cancer therapies act on protein targets but data on the proteome status of patients and cellular models for proteome-guided pre-clinical drug sensitivity studies are only beginning to emerge. Here, we profiled the proteomes of 65 colorectal cancer (CRC) cell lines to a depth of > 10,000 proteins using mass spectrometry. Integration with proteomes of 90 CRC patients and matched transcriptomics data defined integrated CRC subtypes, highlighting cell lines representative of each tumour subtype. Modelling the responses of 52 CRC cell lines to 577 drugs as a function of proteome profiles enabled predicting drug sensitivity for cell lines and patients. Among many novel associations, MERTK was identified as a predictive marker for resistance towards MEK1/2 inhibitors and immunohistochemistry of 1,074 CRC tumours confirmed MERTK as a prognostic survival marker. We provide the proteomic and pharmacological data as a resource to the community to, for example, facilitate the design of innovative prospective clinical trials.
Keyphrases